ARROWHEAD PHARMACEUTICALS, INC. Lease, Cost
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Lease, Cost of $4.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for the quarter ending 2026-06-30 was $4.17M, a 16.50% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for the quarter ending 2026-03-31 was $4.42M, a 6.35% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for the quarter ending 2025-12-31 was $4.19M, a 2.26% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for the quarter ending 2025-09-30 was $4.49M, a 7.40% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for fiscal 2025 was $16.51M, a 1.07% decline from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for fiscal 2024 was $16.69M, a 25.87% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for fiscal 2023 was $13.26M, a 35.81% increase from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. lease, cost for fiscal 2022 was $9.76M, a 63.75% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.17M 10-Q · filed 2026-08-04 | $8.59M derived: sum of 2 quarters · filed 2026-08-04 | $12.78M 10-Q · filed 2026-08-04 | $17.27M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.42M 10-Q · filed 2026-05-07 | $8.62M 10-Q · filed 2026-05-07 | $13.10M derived: sum of 3 quarters · filed 2026-05-07 | $16.68M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.19M 10-Q · filed 2026-02-05 | $8.68M derived: sum of 2 quarters · filed 2026-02-05 | $12.25M derived: sum of 3 quarters · filed 2026-08-04 | $16.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-09-30 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $8.06M derived: sum of 2 quarters · filed 2026-08-04 | $12.22M derived: sum of 3 quarters · filed 2026-08-04 | $16.51M 10-K · filed 2025-11-25 |
| 2025-06-30 | $3.58M 10-Q · filed 2026-08-04 | $7.74M derived: sum of 2 quarters · filed 2026-08-04 | $12.03M 10-Q · filed 2026-08-04 | $16.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $4.16M 10-Q · filed 2026-05-07 | $8.45M 10-Q · filed 2026-05-07 | $12.63M derived: sum of 3 quarters · filed 2026-05-07 | $16.99M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.29M 10-Q · filed 2026-02-05 | $8.46M derived: sum of 2 quarters · filed 2026-02-05 | $12.83M derived: sum of 3 quarters · filed 2026-02-05 | $16.73M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $8.54M derived: sum of 2 quarters · filed 2025-11-25 | $12.44M derived: sum of 3 quarters · filed 2025-11-25 | $16.69M 10-K · filed 2025-11-25 |
| 2024-06-30 | $4.37M 10-Q · filed 2025-08-07 | $8.26M derived: sum of 2 quarters · filed 2025-08-07 | $12.51M 10-Q · filed 2025-08-07 | $15.87M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $3.90M 10-Q · filed 2025-05-12 | $8.15M 10-Q · filed 2025-05-12 | $11.50M derived: sum of 3 quarters · filed 2025-11-25 | $15.59M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $4.25M 10-Q · filed 2025-02-10 | $7.60M derived: sum of 2 quarters · filed 2025-11-25 | $11.69M derived: sum of 3 quarters · filed 2025-11-25 | $14.70M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $7.44M derived: sum of 2 quarters · filed 2025-11-25 | $10.45M derived: sum of 3 quarters · filed 2025-11-25 | $13.26M 10-K · filed 2025-11-25 |
| 2023-06-30 | $4.09M 10-Q · filed 2024-08-08 | $7.09M derived: sum of 2 quarters · filed 2024-08-08 | $9.90M 10-Q · filed 2024-08-08 | $13.10M derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-03-31 | $3.00M 10-Q · filed 2024-05-09 | $5.82M 10-Q · filed 2024-05-09 | $9.01M derived: sum of 3 quarters · filed 2024-11-26 | $12.62M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-12-31 | $2.81M 10-Q · filed 2024-02-06 | $6.01M derived: sum of 2 quarters · filed 2024-11-26 | $9.61M derived: sum of 3 quarters · filed 2024-11-26 | $11.12M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-09-30 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $6.80M derived: sum of 2 quarters · filed 2024-11-26 | $8.31M derived: sum of 3 quarters · filed 2024-11-26 | $9.76M 10-K · filed 2024-11-26 |
| 2022-06-30 | $3.60M 10-Q · filed 2023-08-07 | $5.11M derived: sum of 2 quarters · filed 2023-08-07 | $6.56M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $1.51M 10-Q · filed 2023-05-02 | $2.96M 10-Q · filed 2023-05-02 | ||
| 2021-09-30 | $5.96M 10-K · filed 2023-11-29 | |||
| 2020-09-30 | $3.20M 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |